⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5406946 | 1.00 | — | — | |
| SCHEMBL7168266 | 0.84 | POLB (0.31) | — | |
| SCHEMBL14543004 | 0.83 | — | — | |
| SCHEMBL5403688 | 0.79 | EGFR (0.31) | — | |
| SCHEMBL5403690 | 0.79 | EGFR (0.31) | — | |
| SCHEMBL5406525 | 0.77 | RARB (0.32) | — | |
| SCHEMBL5406530 | 0.77 | RARB (0.32) | — | |
| SCHEMBL5397197 | 0.74 | ALDH1A1 (0.36) | — | |
| SCHEMBL5397192 | 0.74 | ALDH1A1 (0.36) | — | |
| SCHEMBL5405655 | 0.73 | POLA1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208142-B2 | Indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2007-04-24 | — | — | US | claimed |
| US-20020143203-A1 | Novel indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2002-10-03 | — | — | US | claimed |
| US-20070185057-A1 | Novel Indanone Compounds | SYMRISE GMBH & CO. KG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185057-A1 | Novel Indanone Compounds | SYMRISE GMBH & CO. KG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-7208142-B2 | Indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2007-04-24 | — | — | US | disclosed |
| US-7208142-B2 | Indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2007-04-24 | — | — | US | disclosed |
| US-20020143203-A1 | Novel indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2002-10-03 | — | — | US | disclosed |